Irodalom:
1. Dalmi L. és mtsai: Protokoll a krónikus vírushepatitisek antivirális kezelésére. Orvosi Hetil. 2008, 149, 129-135
2. Hunyady B.: A szérum alanin-aminotranszferáz-értéke krónikus C-vírus hepatitisben. Mennyi a “normális”,
és kit kezeljünk? LAM 2007;17(4-5):283-7.
3. Fraser A. et al: Prevalence of elevated aminotransferase among US adolescents. Gastroenterology
2007 133, 1814-1820.
4. Manolakopoulos S. és mtsai): Long-term therapy with adefovir dipivoxil in hepatitisBe-antigén-negatív
patients developing resistance to lamivudine. Aliment. Pharmacol. Therap. 2007, 27, 266-273.
5. Buster E.H.C.J. és mtsai.: Prolonged antiviral therapy for hepatitis B vírus-infected heath care workers:
a feasible option fo prevent work restriction without jeopardizing patient safety. J Viral Hepat. 2007,
14, 350-354.
6. Tornai I., Nemesánszky E.: A krónikus B-vírus-hepatitis kezelési lehetõségei Magyarországon LAM
2006;16(11):927-33.
7. Keefe EB, Dieterich DT, Han SHB.: A treatment algorithm for the management of chronic hepatitis B
virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2007;4:936-962.
8. Leemans WF., Ter Borg MJ., De Man RA.: Review article: success and failure of nucleosid analogues
in chronic hepatitis B. Aliment Pharmacol Ther 2007, 26 (Suppl), 171-182.
9. Pár A. és mtsai.: A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998-2004)
Orv. Hetil. 2007, 148, 819-826.
10. Horváth G. és mtsai: Normális ALT-szintû, krónikus C hepatítisben szenvedõ betegek kezelése. LAM
2007, 17, 777-781.
11. DiMarco V. és mtsai: (11) Peg-interferon alone or in combined with ribavirin in HCV cirrhosis with
portal hypertension: a randimised controlled trial. J Hepatol. 2007, 47, 484-491.
12. Jensen G.S., Trotter J.F.: Treatment of chronic HCV in advansed liver disease: unmet challenges, reason
for optimism (Editorial) . J Hepatol. 2007, 47, 441-443.
13. DiBiscegglieA. M. és mtsai:Pharmacokinetics and pharmacodynamics of pegylated interferon alfa 2a or
alfa-2b with ribavirin in treatment naiv patients with genotype 1 chronic hepatitis C. Hepatology 2004, 40,
(Suppl-1.) 734.
14. Silva M. és mtsai: A randomised trial to compare the pharmacokinetic, pharmacodinamic and antiviral
effects of peginterferon alfa-2b and peginterferon alfa-2a patients with chronic hepatitis C (COMPARE)
J Hepatol. 2006, 45, 204-213.
15. McHutchison J., Sulkowski M.: PR-Newswire-FirstCall-Schering-Plough Corporation: www.idealstudy.com
(Jan.14)
16. Rustgi V.K. és mtsai: (16)(Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or
nonresponsive to peginterferon alfa-2b/ribavirin. Aliment. Pharmacol. Therap. 2007, 27, 443-440.
17. Saches-Tapas JM. és mtsai: Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patientswith
detectable hepatitis C vírus RNS at 4 week of treatment. Gastroenterology 2006, 131, 451-460
18. Berg Th. és mtsai: Extended treatment for hepatitis C type-1: comparing 48 vesus 72 weeks of
peginterferon-apha-2a plus ribavirin. Gastroenterology 2006, 130, 1086-1097
19. Telegdy L. és mtsai: A humán leukocytainterferon helye a krónikus hepatitis C kezelésében LAM
2007;17(11):783-786.
20. Reddy KR, Shiffman ML, Morgan TR, et al: Impact of ribavirin dose reductions in hepatitis C virus
A máj 329
genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol.
2007;5:124-129.
21. Shiffman ML, Ghany MG, Morgan TR, et al: Impact of reducing peginterferon alfa-2a and ribavirin
dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103-112.
22. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V.: Pegylatedinterferon and ribavirin
failures: is retreatment an option? Dig Dis Sci. 2007;52:732-736.
23. Poynard T, Schiff E, Terg R, et al: Sustained virologic response (SVR) in the EPIC3 trial: week twelve
virology predicts SVR in previous interferon/ribavirin treatment failures receiving Peg-Intron/Rebetol
(PR) weight based dosing (WBD). Program and abstracts of the 40th Annual Meeting of the European
Association for the Study of the Liver; April 13-17, 2005; Paris, France. Abstract 96.
24. Colsalvo R.: Therapy for retreating hepatitis C patients who failed previous therapy (EPIC-3).
Newswire, 2007 september 24.
25. Afdahl N, O’Brien C, Godofsky E, et al: Valopicitabine (NM283), alone or with peginterferon, compared
to peginterferon/ribavirin retreatment in patients with HCV-1 infection and prior non-response to
pegIFN/RBV: one year results. Program and abstracts of the 2007 Annual Meeting of the European
Association for the Study of the Liver; April 11-15, 2007; Barcelona, Spain. Abstract.
